LUXOTTICA GROUP SPA Form 6-K November 09, 2015

Use these links to rapidly review the document <u>TABLE OF CONTENTS</u>

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTER ENDED SEPTEMBER 30, 2015 COMMISSION FILE NO. 1 - 10421

LUXOTTICA GROUP S.p.A.

PIAZZALE LUIGI CADORNA 3, MILAN, 20123 ITALY (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ý Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No ý

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-____

INDEX TO FORM 6-K

Item 1 M	Anagement report on the interim consolidated financial results as of September 30, 2015	<u>1</u>
Item 2 F	Financial Statements:	
	Consolidated Statement of Financial Position for the periods ended September 30, 2015 and December 31, 2014	<u>21</u>
	<u>Consolidated Statement of Income for the three-month periods ended September 30, 2015 and 2014 and for the nine-month periods ended September 30, 2015 and 2014</u>	<u>22</u>
	Consolidated Statement of Comprehensive Income for the three-month periods ended September 30, 2015 and 2014 and for the nine-month periods ended September 30, 2015 and 2014	<u>23</u>
	Consolidated Statement of Changes in Equity for the periods ended September 30, 2015 and 2014	<u>24</u>
	Consolidated Statement of Cash Flows for the periods ended September 30, 2015 and 2014	<u>25</u>
	<u>Consolidated Statement of Financial Position as of September 30, 2015 and December 31, 2014 pursuant to</u> <u>Consob Resolution No. 15519 dated July 27, 2006</u>	<u>27</u>
	Notes to the Condensed Consolidated Financial Statements as of September 30, 2015	<u>29</u>
<u>Attachmen</u>	<u>Exchange rates used to translate financial statements prepared in currencies other than the Euro</u>	<u>55</u>
Attachmen	<u>Certification of the consolidated financial statements pursuant to Article 154-bis of Legislative Decree 58/98</u>	<u>56</u>

Table of Contents

Corporate Management

Board of Directors

In office until the approval of the financial statements as of and for the year ending December 31, 2017

Chairman Deputy Chairman CEO Markets CEO Product and Operations Directors Leonardo Del Vecchio Luigi Francavilla Adil Mehboob-Khan Massimo Vian Marina Brogi* (Lead independent Director) Luigi Feola* Elisabetta Magistretti* Mario Notari Karl Heinz Salzburger* Maria Pierdicchi* Luciano Santel* Cristina Scocchia* Sandro Veronesi* Andrea Zappia*

Independent director

Human Resources Committee

Internal Control Committee

Board of Statutory Auditors

In office until the approval of the financial statements as of and for the year ending December 31, 2017

Regular Auditors

Alternate Auditors

Officer Responsible for Preparing the Company's Financial Reports

Alberto Giussani Barbara Tadolini

Francesco Vella (Chairman)

Andrea Zappia (President)

Elisabetta Magistretti (Chairperson)

Marina Brogi Mario Notari

Luciano Santel Cristina Scocchia

Maria Venturini Roberto Miccù

Stefano Grassi

 Auditing Firm
 PricewaterhouseCoopers SpA

 Until approval of the financial statements as of and for the year ending December 31, 2020

Table of Contents

Luxottica Group S.p.A.

Headquarters and registered office • Piazzale Luigi Cadorna, 3, 20123 Milan, Italy Capital Stock € 29,007,115.98 authorized and issued

ITEM 1. MANAGEMENT REPORT ON THE INTERIM FINANCIAL RESULTS AS OF SEPTEMBER 30, 2015 (UNAUDITED)

The following should be read in connection with the disclosure contained in the consolidated financial statements as of December 31, 2014, which includes a discussion of risks and uncertainties that can influence the Group's operational results or financial position. During the first nine months of 2015, there were no changes to risks that were reported as of December 31, 2014.

1. OPERATING PERFORMANCE FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2015

The Group's growth in the first nine months of 2015 was significantly impacted by the strengthening of certain currencies in which it operates. At constant exchange rates⁽¹⁾, the Group confirmed solid growth in the primary markets in which it conducts business.

Net sales increased from Euro 5,785.3 million in the first nine months of 2014 to Euro 6,821.7 million in the first nine months of 2015 (+17.9 percent at current exchange rates and +5.0 percent at constant exchange rates⁽¹⁾). Adjusted net sales⁽²⁾ increased to Euro 6,951.7 million in the first nine months of 2015 (+19.7 percent at current exchange rates and +6.4 percent at constant exchange rates⁽¹⁾). Adjusted net sales⁽²⁾ increased to Euro 6,951.7 million in the first nine months of 2015 (+19.7 percent at current exchange rates and +6.4 percent at constant exchange rates⁽¹⁾). Adjusted net sales were impacted, starting from July 1, 2014, by the modification of an EyeMed reinsurance agreement with an existing underwriter whereby the Company assumes less reinsurance revenues and less claims expense. The impact of this contract for the nine-month periods ended September 30, 2015 and 2014 is a reduction in net sales with a corresponding reduction in cost of sales of Euro 130.0 million and Euro 22.7 million, respectively (the "EyeMed Adjustment").

Earnings before Interest, Taxes, Depreciation and Amortization ("EBITDA")⁽³⁾ in the first nine months of 2015 increased by 26.1 percent to Euro 1,548.5 million from Euro 1,227.6 in the first nine months of 2014.

Adjusted Earnings before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA")⁽³⁾, which in 2015 excludes Oakley's integration and other minor projects costs and in 2014 excludes the non-recurring expenses related to the termination of the former Group CEO, in the first nine months of 2015 increased by Euro 340.0 million or 27.4 percent, to Euro 1,582.6 million from Euro 1,242.6 in the first nine months of 2014.

Operating income for the first nine months of 2015 increased by 26.2 percent to Euro 1,196.2 million from Euro 947.5 million during the same period of the previous year. The Group's operating margin continued to grow, rising from 16.4 percent in 2014 to 17.5 percent in 2015.

Adjusted operating income⁽⁴⁾ for the first nine months of 2015 increased by 27.8 percent to Euro 1,230.3 million compared to adjusted operating income⁽⁴⁾ for the same period in 2014 of Euro 962.5 million. The Group's adjusted operating margin⁽⁵⁾ continued to grow, rising from 16.6 percent in 2014 to 17.7 percent in 2015.

(2)

(3)

(4)

(5)

⁽¹⁾

We calculate constant exchange rates by applying to the current period the average exchange rates between the Euro and the relevant currencies of the various markets in which we operated during the nine-month period ended September 30, 2014. Please refer to Attachment 1 for further details on exchange rates.

For a further discussion of adjusted net sales, see page 13 "Non-IFRS Measures.".

For a further discussion of EBITDA and adjusted EBITDA, see page 13 "Non-IFRS Measures."

For a further discussion of adjusted operating income see page 13 "Non-IFRS Measures."

For a further discussion of adjusted operating margin see page 13 "Non-IFRS Measures."

Table of Contents

In the first nine months of 2015, net income attributable to Luxottica Stockholders increased by 27.0 percent to Euro 704.8 million from Euro 555.0 million in the same period of 2014. Earnings per share ("EPS") was Euro 1.47.

In the first nine months of 2015, adjusted net income attributable to Luxottica Stockholders⁽⁶⁾ increased by 29.7 percent to Euro 733.7 million from Euro 565.9 million in the comparable period in 2014. Adjusted earnings per share⁽⁷⁾ ("Adjusted EPS") was Euro 1.53.

Careful control of our working capital as well as a significant improvement in our operating results lead to strong free cash flow⁽⁸⁾ generation equal to Euro 695.0 million. Net debt as of September 30, 2015 was Euro 1,050.1 million (Euro 1,012.9 million at the end of 2014), with a ratio of net debt to EBITDA⁽⁹⁾ of 0.6 (0.7x as of December 31, 2014).

2. SIGNIFICANT EVENTS DURING THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2015

January

On January 19, 2015 the Board of Directors appointed Adil Mehboob-Khan as the Group CEO for Markets and Massimo Vian as the Group CEO for Product and Operations. The appointment of Adil Mehboob-Khan and Massimo Vian, entrusting them with all executive responsibilities, completed the Group's organizational change process which is aimed at providing governance that is more aligned to the global competitive landscape and able to fully grasp growth opportunities. It also unites the Group's organizational model with its strategic vision.

April

At the Stockholders' Meeting on April 24, 2015, Group's stockholders approved the Statutory Financial Statements as of December 31, 2014 as proposed by the Board of Directors and the distribution of a cash dividend of Euro 1.44 per ordinary share. The aggregate dividend amount of Euro 689.7 million was fully paid in May 2015.

May

On May 14, 2015, the Company and Prada S.p.A., part of Prada Group, announced the renewal of an exclusive license agreement for the design, production and worldwide distribution of prescription frames and sunglasses under the Prada and Miu Miu brands. The 10-year agreement will extend through December 31, 2025.

On May 19, 2015, the Company announced the grant of free treasury shares to the Group's employees in Italy in honor of the 80th birthday of its Chairman and Founder, Mr. Leonardo Del Vecchio. This share award is a gift from the Founder with an aggregate amount of 119,755 Luxottica Group treasury shares distributed. Delfin S.à.r.l. assumed all costs and expenses of the share grant.

June

On June 25, 2015, the Company signed an agreement to enhance the market liquidity of its shares in compliance with CONSOB's market practices permitted under resolution no. 16839 adopted on March 19, 2009 regarding activity to support market liquidity. The agreement is between the Company and Kepler Capital Markets SA (the "Intermediary"), with its corporate headquarters in Paris, France, Avenue Kléber, 112 and registered with the Paris Commercial Register n. 413 064 841.

(8)

(9)

⁽⁶⁾ (7)

For a further discussion of adjusted net income attributable to Luxottica Stockholders see page 13 "Non-IFRS Measures."

For a further discussion of adjusted earnings per share see page 13 "Non-IFRS Measures."

For a further discussion of free cash flow, see page 13 "Non-IFRS Measures."

For a further discussion of net debt and net debt to adjusted EBITDA, see page 13 "Non-IFRS Measures."

Table of Contents

July

On July 1, 2015, the Series B Senior Unsecured Notes issued in a private placement by Luxottica U.S. Holdings Corp. on July 1, 2008 matured and were fully repaid in the amount of U.S.\$ 127.0 million.

On July 29, 2015, the Company and Burberry Group announced the renewal of an exclusive license agreement for the development, production and worldwide distribution of sunglasses and prescription frames under the Burberry name. The 10-year agreement will extend to December 31, 2025.

3. FINANCIAL RESULTS

We are a market leader in the design, manufacture and distribution of fashion, luxury, sport and performance eyewear, with net sales reaching over Euro 7.6 billion in 2014, approximately 78,000 employees and a strong global presence. We operate in two industry segments: (i) manufacturing and wholesale distribution; and (ii) retail distribution. See Note 5 of the Notes to the Consolidated Financial Statements as of September 30, 2015 for additional disclosures about our operating segments. Through our manufacturing and wholesale distribution segment, we are engaged in the design, manufacture, wholesale distribution and marketing of proprietary and designer lines of mid- to premium-priced prescription frames and sunglasses. We operate our retail distribution segment principally through our retail brands, which include, among others, LensCrafters, Sunglass Hut, OPSM, Pearle Vision, Laubman & Pank, Oakley "O" Stores and Vaults, David Clulow, GMO and our Licensed Brands (Sears Optical and Target Optical).

As a result of our numerous acquisitions and the subsequent expansion of our business activities in the United States through these acquisitions, our results of operations, which are reported in Euro, are susceptible to currency rate fluctuations between the Euro and the U.S. dollar. The Euro/U.S. dollar exchange rate has fluctuated to an average exchange rate of Euro 1.00 = U.S. \$1.1144 in the first nine months of 2015 from Euro 1.00 = U.S. \$1.3549 in the first nine months of 2014. With the acquisition of OPSM and other businesses, our results of operations have been rendered more susceptible to currency fluctuations between the Euro and the Australian Dollar. Additionally, we incur part of our manufacturing costs in Chinese Yuan; therefore, the fluctuation of the Chinese Yuan could impact the demand of our products or our consolidated profitability. Although we engage in certain foreign currency hedging activities to mitigate the impact of these fluctuations, they have impacted our reported revenues and expenses during the periods discussed herein. The Group does not engage in long-term hedging activities to mitigate translation risk. This discussion should be read in conjunction with the risk factor discussion in Section 8 of the Management Report included with the 2014 Consolidated Financial Statements.

RESULTS OF OPERATIONS FOR THE NINE-MONTHS ENDED SEPTEMBER 30, 2015 AND 2014

	Nine months ended September 30,			
		% of		% of
(Amounts in thousands of Euro)	2015	net sales	2014	net sales
Net sales	6,821,688	100%	5,785,282	100.0%
Cost of sales	2,165,220	31.7%	1,955,366	33.8%
Gross profit	4,656,468	68.3%	3,829,916	66.2%
Selling	2,088,281	30.6%	1,710,560	29.6%
Royalties	130,644	1.9%	112,352	1.9%
Advertising	441,294	6.5%	381,202	6.6%
General and administrative	800,099	11.7%	678,260	11.7%
Total operating expenses	3,460,318	50.7%	2,882,375	49.8%
Income from operations	1,196,150	17.5%	947,541	16.4%
Other income/(expense)				
Interest income	7,967	0.1%	8,994	0.2%
Interest expense	(84,347)	(1.2)%	(80,764)	(1.4)%
Other net	531	0.0%	(367)	(0.0)%
Income before provision for income taxes	1,120,301	16.4%	875,405	15.1%
Provision for income taxes	(413,411)	(6.1)%	(316,373)	(5.5)%
Net income	706,891	10.4%	559,031	9.7%
Attributable to				
Luxottica Group stockholders	704,768	10.3%	554,982	9.6%
non-controlling interests	2,123	0.0%	4,049	0.1%
NET INCOME	706,891	10.4%	559,031	9.7%

Nine months ended September 30,

In order to represent the Group's operating performance on a consistent basis in this Management Report, net sales and operating expenses in 2015 as represented in the Group's Consolidated Financial Statements have been adjusted in the tables below to take into account the following events:

EyeMed Adjustment (as defined above) which is equal to Euro 130.0 million for the nine-month period ended September 30, 2015; and

The Group incurred costs of Euro 34.1 million related to the reorganization of Oakley and for other minor projects for the nine-month period ended September 30, 2015.

Additional adjustments for other periods included in this report are described in the " Non-IFRS Measures" section.

Net Sales. Net sales increased by Euro 1,036.4 million, or 17.9% to Euro 6,821.7 million in the first nine months of 2015 from Euro 5,785.3 million in the same period of 2014. Euro 344.5 million and Euro 691.9 million of this increase was attributable to increased sales in the manufacturing and wholesale distribution segment and the retail distribution segment, respectively. Euro 746.8 million of the total increase of Euro 1,036.4 million is due to the strengthening of certain currencies compared to the Euro. Adjusted net sales⁽¹⁰⁾ for the nine-month period in

2015, which include the EyeMed Adjustment of Euro 130.0 million, were Euro 6,951.7 million.

(10)

For a further discussion of adjusted net sales, see page 13 "Non-IFRS Measures."

4

Please find the reconciliation between adjusted⁽¹⁰⁾ net sales and net sales in the following table:

(Amounts in million of Euro)	September 30, 2015	September 30, 2014
Net sales	6,821,7	5,785.3
> EyeMed Adjustment	130.0	22.7
Adjusted net sales	6,951.7	5,808.0

Net sales for the retail distribution segment increased by Euro 691.9 million, or 21.0%, to Euro 3,987.6 million in the first nine months of 2015 from Euro 3,295.8 million in the same period of 2014. The effects from currency fluctuations between the Euro, which is our reporting currency, and the other currencies in which we conduct business, in particular the strengthening of the U.S. dollar and the Australian dollar compared to the Euro, increased net sales in the retail distribution segment by Euro 573.8 million. In addition, the increase in net sales for the period was partially attributable to a 4.5% increase in comparable store⁽¹¹⁾ sales. Adjusted net sales⁽¹⁰⁾ of the retail division in the first nine months of 2015, which include the Eyemed Adjustment of Euro 130.0 million, were Euro 4,117.7 million.

Please find the reconciliation between adjusted⁽¹⁰⁾ net sales of the retail division and net sales of the retail division in the following table:

(Amounts in millions of Euro)	September 30, 2015	September 30, 2014
Net sales retail division	3,987.6	3,295.8
> EyeMed Adjustment	130.0	22.7
Adjusted net sales retail division	4,117.7	3,318.4

Net sales to third parties in the manufacturing and wholesale distribution segment increased in the first nine months of 2015 by Euro 344.5 million, or 13.8%, to Euro 2,834.1 million from Euro 2,489.5 million in the same period of 2014. This increase occurred in most geographic areas in which the Group operates and was impacted by positive currency fluctuations, in particular the strengthening of the U.S. dollar and Australian dollar compared to the Euro, which increased net sales in the wholesale distribution segment by Euro 173.0 million. Additionally, sales increased for most of our proprietary brands, in particular Ray-Ban and Oakley and for certain designer brands including Prada, Polo Ralph Lauren, Armani and Michael Kors.

In the first nine months of 2015, net sales in the retail distribution segment accounted for approximately 58.5% of total net sales, as compared to approximately 57.0% of total net sales in the same period of 2014.

In the first nine months of 2015 and 2014, net sales in our retail distribution segment in the United States and Canada comprised 78.6% and 77.5%, respectively, of our total net sales in this segment. In U.S. dollars, retail net sales in the United States and Canada increased by 1.9% to U.S. \$ 3,525.2 million in the first nine months of 2015 from U.S. \$ 3,458.5 million in the same period of 2014. During the first nine months of 2015, net sales in the retail distribution segment in the rest of the world (excluding the United States and Canada) comprised 21.4% of our total net sales in the retail distribution segment and increased by 14.9% to Euro 854.0 million in the first nine months of 2015 from Euro 743.2 million, or 22.5% of our total net sales in the retail distribution segment, in the same period of 2014, mainly due to positive currency fluctuations.

(11)

Comparable store sales reflects the change in sales from one period to another that, for comparison purposes, includes in the calculation only stores open in the more recent period that also were open during the comparable prior period in the same geographic area, and applies to both periods the average exchange rate for the prior period.

Table of Contents

In the first nine months of 2015, net sales to third parties in our manufacturing and wholesale distribution segment in Europe were Euro 1,105.0 million, comprising 39.0% of our total net sales in this segment, compared to Euro 1,046.0 million, or 42.0% of total net sales in this segment in the same period of 2014, increasing by Euro 59.0 million or 5.6% in 2015 as compared to the same period of 2014. Net sales to third parties in our manufacturing and wholesale distribution segment in the United States and Canada were U.S. \$943.7 million and comprised 29.4% of our total net sales in this segment in the first nine months of 2015, compared to U.S. \$878.8 million, or 26.1% of total net sales in this segment, in the same period of 2014. The increase in net sales in the United States and Canada was primarily due to a general increase in consumer demand. In the first nine months of 2015, net sales to third parties in our manufacturing and wholesale distribution segment in the united states and Canada was primarily due to a general increase in consumer demand. In the first nine months of 2015, net sales to third parties in our manufacturing and wholesale distribution segment in the rest of the world were Euro 895.8 million, comprising 31.6% of our total net sales in this segment, compared to Euro 794.9 million, or 31.9% of our net sales in this segment, in the same period of 2014, with an increase of Euro 100.9 million, or 12.7%, as of September 30 2015 as compared to the same period of 2014.

Cost of Sales. Cost of sales increased by Euro 209.9 million, or 10.7%, to Euro 2,165.2 million in the first nine months of 2015 from Euro 1,955.4 million in the same period of 2014. As a percentage of net sales, cost of sales was 31.7% and 33.8% in the first nine months of 2015 and 2014, respectively, with the percentage year-over-year change primarily driven by production efficiencies and the Eyemed Adjustment. In the first nine months of 2015, the average number of frames produced daily in our facilities increased to approximately 354,000 as compared to approximately 295,000 in the same period of 2014. Adjusted cost of sales⁽¹²⁾ of the retail distribution segment in the first nine months of 2015, which include the EyeMed Adjustment of Euro 130.0 million, was Euro 2,295.2 million.

Please find the reconciliation between adjusted cost of sales⁽¹²⁾ and cost of sales in the following table:

(Amounts in millions of Euro)	September 30, 2015	September 30, 2014
Cost of sales	2,165.2	1,955.4
> Eyemed Adjustment	130.0	22.7
Adjusted cost of sales	2,295.2	1,978.0

Gross Profit. Our gross profit increased by Euro 826.6 million, or 21.6%, to Euro 4,656.5 million in the first nine months of 2015 from Euro 3,829.9 million in the same period of 2014. As a percentage of net sales, gross profit increased to 68.3% in the first nine months of 2015 from 66.2% in the same period of 2014.

Operating Expenses. Total operating expenses increased by Euro 577.9 million, or 20.1%, to Euro 3,460.3 million in the first nine months of 2015 from Euro 2,882.4 million in the same period of 2014. As a percentage of net sales, operating expenses increased to 50.7% in the first nine months of 2015 from 49.8% in the same period of 2014. The increase is due to (i) the costs incurred for Oakley's integration and other minor projects; and (ii) the overall growth of the Group's business. Adjusted operating expenses of Euro 15.0 million related to the termination of the former Group CEO, increased by Euro 558.8 million to Euro 3,426.2 million. As a percentage of adjusted net sales⁽¹⁰⁾, adjusted operating expenses⁽¹³⁾ were 49.3% and 49.4% in the first nine months of 2015 and 2014, respectively.

⁽¹²⁾For a further discussion of adjusted cost of sales, see page 13 "Non-IFRS Measures."
(13)
For a further discussion of adjusted operating expenses, see page 13 "Non-IFRS Measures."

⁶

Please find the reconciliation between adjusted operating expenses⁽¹³⁾ and operating expenses in the following table:

(Amounts in millions of Euro)	September 30, 2015	September 30, 2014
Operating expenses	3,460.3	2,882.4
> Adjustment for termination of the former Group CEO		(15.0)
> Oakley's integration and other minor project costs	(34.1)	
Adjusted operating expenses	3.426.2	2,867,4

Selling and advertising expenses (including royalty expenses) increased by Euro 456.1 million, or 20.7%, to Euro 2,660.2 million in the first nine months of 2015 from Euro 2,204.1 million in the same period of 2014. Selling expenses increased by Euro 377.7 million, or 22.1%. Advertising expenses increased by Euro 60.1 million, or 15.8%. Royalties increased by Euro 18.3 million, or 16.3%. As a percentage of net sales selling and advertising expenses were 39.0% and 38.1% in the first nine months of 2015 and 2014, respectively. This increase is mainly due to the strengthening of certain currencies in which the Group operates.

Adjusted selling and advertising expenses⁽¹⁴⁾ (including royalty expenses), excluding for 2015 Oakley's integration and other minor project costs of Euro 1.0 million, were Euro 2,659.2 million. As a percentage of adjusted net sales⁽¹⁰⁾ adjusted selling and advertising expenses⁽¹⁴⁾ were 38.3% and 37.9% in the first nine months of 2015 and 2014, respectively.

Please find the reconciliation between adjusted selling and advertising expenses⁽¹⁴⁾ and selling and advertising expenses in the following table:

(Amounts in millions of Euro)	September 30, 2015	September 30, 2014
Selling and advertising expenses	2,660.2	2,204.1
> Oakley's integration and other minor project costs	(1.0)	
Adjusted Selling and advertising expenses	2,659.2	2,204.1

General and administrative expenses, including intangible asset amortization, increased by Euro 121.8 million, or 18.0%, to Euro 800.1 million in the first nine months of 2015, as compared to Euro 678.3 million in the same period of 2014. As a percentage of net sales, general and administrative expenses were 11.7% in the first nine months of 2015, in line with the same period of 2014. The increase is mainly due to the integration costs of Oakley and other minor project costs of Euro 33.1 million, the strengthening of certain currencies in which the Group operates and to the overall growth of the business of the Group.

Adjusted general and administrative expenses⁽¹⁵⁾, including intangible asset amortization and excluding for 2015 Oakley's integration and other minor project costs of Euro 33.1 million and for 2014 the non-recurring expenses of Euro 15.0 million related to the termination of the former Group CEO, were Euro 767.0 million and Euro 663.3 million in the first nine months of 2015 and in 2014, respectively. As a percentage of adjusted net sales⁽¹⁰⁾, adjusted general and administrative expenses⁽¹⁵⁾ were 11.0% in the first nine months of 2015 and 2014, respectively.

For a further discussion of adjusted selling and advertising expenses, see page 13 "Non-IFRS Measures."

For a further discussion of adjusted general and administrative expenses , see page 13 "Non-IFRS Measures."

⁽¹⁴⁾

Please find the reconciliation between adjusted general and administrative expenses⁽¹⁵⁾ and general and administrative expenses in the following table:

(Amounts in millions of Euro)	September 30, 2015	September 30, 2014
General and administrative expenses	800.1	678.3
> Adjustment for termination of the former Group CEO		(15.0)
> Oakley's integration and other minor project costs	(33.1)	
Adjusted general and administrative expenses	767.0	663.3

Income from Operations. For the reasons described above, income from operations increased by Euro 248.7 million to Euro 1,196.2 million in the first nine months of 2015 from Euro 947.5 million in the same period of 2014. As a percentage of net sales, income from operations increased to 17.5% in 2015 from 16.4% in 2014. Adjusted income from operations⁽¹⁶⁾, excluding for 2015 Oakley's integration costs and the costs of other minor projects of Euro 34.1 million and for 2014 the non-recurring expenses of Euro 15.0 million related to the termination of the former Group CEO, increased by Euro 267.8 million to Euro 1,230.3 million in the first nine months of 2015 from Euro 962.5 million in the same period of 2014. As a percentage of adjusted net sales⁽¹⁰⁾, adjusted income from operations⁽¹⁶⁾ was 17.7% and 16.6% in the first nine months of 2015 and 2014, respectively.

Please find the reconciliation between adjusted income from operations⁽¹⁶⁾ and income from operations in the following table:

(Amounts in millions of Euro)	September 30, 2015	September 30, 2014
Income from operations	1,196.2	947.5
> Adjustment for termination of the former Group CEO		15.0
> Oakley's integration and other minor project costs	34.1	
Adjusted Income from operations	1,230.3	962.5

Other Income (Expense) Net. Other income (expense) net was Euro (75.8) million in the first nine months of 2015 as compared to Euro (72.1) million in the same period of 2014. Net interest expense was Euro 76.4 million in the first nine months of 2015 as compared to Euro 71.8 million in the same period of 2014. The increase was mainly due to the strengthening of the U.S. dollar against the Euro and cancellation of the revolving credit facility in the amount of Euro 500 million, which resulted in the write-down of approximately Euro 3.9 million of capitalized financing costs.

Net Income. Income before taxes increased by Euro 244.9 million, or 28.0% to Euro 1,120.3 million in the first nine months of 2015 from Euro 875.4 million in the same period of 2014. As a percentage of net sales, income before taxes increased to 16.4% in 2015, from 15.1% in 2014.

Our effective tax rate was 36.9% and 36.1% in the first nine months of 2015 and 2014, respectively.

Net income attributable to non-controlling interests was equal to Euro 2.1 million and Euro 4.0 million, in the first nine months of 2015 and 2014, respectively.

Net income attributable to Luxottica Group stockholders increased by Euro 149.8 million, or 27.0% to Euro 704.8 million in the first nine months of 2015 from Euro 555.0 million in the same period of 2014. Net income attributable to Luxottica Group stockholders as a percentage of net sales increased to 10.3% in the first nine months of 2015 from 9.6% in 2014. Adjusted net income attributable to Luxottica Group

For a further discussion of adjusted income from operations, see page 13 "Non-IFRS Measures."

Table of Contents

stockholders⁽¹⁷⁾, excluding for 2015 Oakley's integration and other minor project costs of Euro 28.9 million and for 2014 non-recurring expenses of Euro 10.9 million related to the termination of the former Group CEO, increased by Euro 167.8 million to Euro 733.7 million from Euro 565.9 million. As a percentage of adjusted net sales⁽¹⁰⁾, adjusted net income attributable to Luxottica Group stockholders⁽¹⁷⁾ was 10.6%.

Please find the reconciliation between adjusted net income attributable to Luxottica Group stockholders⁽¹⁷⁾ and net income attributable to Luxottica Group stockholders in the following table:

(Amounts in millions of Euro)	September 30, 2015	September 30, 2014
Net income attributable Luxottica Stockholders	704.8	555.0
> Adjustment for termination of the former Group CEO		10.9
> Oakley's integration and other minor project costs	28.9	
Adjusted Net income attributable Luxottica Stockholders	733.7	565.9

Basic earnings per share were Euro 1.47 in the first nine months of 2015 and Euro 1.17 in the same period of 2014. Adjusted basic earnings per share⁽¹⁸⁾ was Euro 1.53 in the first nine months of 2015 and Euro 1.19 in the same period of 2014.

OUR CASH FLOWS

The following table sets forth certain items included in our statements of consolidated cash flows included in Item 2 of this report for the periods indicated.

(Amo	ounts in thousands of Euro)	As of September 30, 2015	As of September 30, 2014
A)	Cash and cash equivalents at the beginning of the period	1,453,587	617,995
B)	Net cash provided by operating activities	1,020,438	935,910
C)	Cash provided/(used) in investing activities	(371,338)	(311,227)
D)	Cash provided/(used) in financing activities	(828,944)	11,069
E)	Effect of exchange rate changes on cash and cash equivalents	40,689	44,302
F)	Net change in cash and cash equivalents	(139,155)	680,054
G)	Cash and cash equivalents at the end of the period	1,314,432	1,298,049

Operating Activities. The Company's net cash provided by operating activities in the first nine months of 2015 and 2014 was Euro 1,020.4 million and Euro 935.9 million, respectively.

Depreciation and amortization were Euro 352.4 million in the first nine months of 2015 as compared to Euro 280.0 million in the same period of 2014. The increase is mainly due to the strengthening of certain currencies in which the Groups operates.

(17)(18)

For a further discussion of adjusted net income attributable to Luxottica Stockholders, see page 13 "Non-IFRS Measures."

For a further discussion of adjusted basic earning per share, see page 13 "Non-IFRS Measures."

Table of Contents

The change in accounts receivable was Euro (99.2) million in the first nine months of 2015 as compared to Euro (79.2) million in the same period of 2014. This change in the first nine months of 2015 as compared to 2014 was primarily due to the higher volume of sales. The change in inventory was Euro (88.2) million in the first nine months of 2015 as compared to Euro 21.9 million in the first nine months of 2014. The increase in inventory in 2015 is aimed at improving the quality of the customer experience by having inventory levels in line with customer demand. The change in accounts payable was Euro 50.6 million in the first nine months of 2015 as compared to Euro 0.3 million in the same period of 2014. The change as compared to previous year was primarily due to the continuous improvement in payment terms and conditions and to the overall growth of the Group's business. The change in other assets and liabilities was Euro (22.3) million in the first nine months of 2014, respectively. The change in the first nine months of 2015 as compared to the same period of 2014 was primarily due to the timing of payments of salaries to store personnel in the retail division in North America. Income taxes paid in the first nine months of 2015 was due to the Italian entities of the Group and, in particular, to the payment of Euro (91.6) million related to the tax audit of Luxottica S.r.l. for the tax years from 2008 to 2011 and to a general increase in the Group's taxable income. Interest paid was Euro (80.6) million as compared to Euro (62.0) million in the first nine months of 2014, respectively. The increase is mainly due to interest accruing on bonds that were issued by the Group during the first nine months of 2014, respectively. The increase is mainly due to interest accruing on bonds that were issued by the Group during the first nine months of 2014, respectively. The increase is mainly due to interest accruing on bonds that were issued by the Group during the first nine months of 2014 with payments being made with re

Investing Activities. The Company's net cash used in investing activities was Euro (371.3) million and Euro (311.2) million in the first nine months of 2015 and 2014, respectively. The primary investment activities in the first nine months of 2015 were related to (i) the purchase of tangible assets for Euro (239.6) million, (ii) the acquisition of intangible assets for Euro (113.8) million and (iii) the acquisition of the remaining 49% of Luxottica Netherlands for Euro (19.0) million. The primary investment activities in the first nine months of 2014 were related to (i) the purchase of tangible assets for Euro (177.3) million, (ii) the acquisition of intangible assets for Euro (94.6) million and (iii) Euro (29.5) million related to the acquisition of glasses.com and other minor acquisitions related to the Retail segment for Euro (9.9) million.

Financing Activities. The Company's net cash provided by/(used in) financing activities was Euro (828.9) million and Euro 11.1 million in the first nine months of 2015 and 2014, respectively. Cash used in financing activities in the first nine months of 2015 consisted (i) primarily of (689.7) million related to the payment of dividends to the Company's shareholders and (ii) of Euro (138.4) million related to the payment of existing debt. Cash generated in the first nine months of 2014 was due to (i) Euro 500 million related to the issuance of bonds and (ii) Euro 55.5 million related to the exercise of stock options. This was offset in 2014 by (i) Euro (318.3) million related to the payment of existing debt and (ii) Euro (308.3) million used to pay dividends to the shareholders of the Company.

10

OUR CONSOLIDATED STATEMENT OF FINANCIAL POSITION

ASSETS (Amounts in thousands of Euro)	September 30, 2015	December 31, 2014
CURRENT ASSETS:		
Cash and cash equivalents	1,314,432	1,453,587
Accounts receivable net	837,618	754,306
Inventories net	822,849	728,404
Other assets	192,714	231,397
Total current assets	3,167,614	3,167,695
NON-CURRENT ASSETS:		
Property, plant and equipment net	1,372,162	1,317,617
Goodwill	3,489,986	3,351,263
Intangible assets net	1,410,001	1,384,501
Investments	62,269	61,176
Other assets	107,670	123,848
Deferred tax assets	195,949	188,199
Total non-current assets	6,638,037	6,426,603
TOTAL ASSETS	9,805,650	9,594,297

LIABILITIES AND STOCKHOLDERS' EQUITY	September 30, 2015	December 31, 2014
CURRENT LIABILITIES:		
Short term borrowings	110,663	151,303
Current portion of long-term debt	554,557	626,788
Accounts payable	784,671	744,272
Income taxes payable	174,685	42,603
Short term provisions for risks and other charges	127,318	187,719
Other liabilities	616,057	636,055
Total current liabilities	2,367,951	2,388,740
NON-CURRENT LIABILITIES:		
Long-term debt	1,699,265	1,688,415
Employee benefits	145,923	138,475
Deferred tax liabilities	254,175	266,896
Long term provisions for risks and other charges	91,240	99,223
Other liabilities	89,578	83,770
Total non-current liabilities	2,280,182	2,276,778
STOCKHOLDERS' EQUITY:		
Luxottica Group stockholders' equity	5,153,171	4,921,479
Non-controlling interests	4,347	7,300
Total stockholders' equity	5,157,519	4,928,779
A v	· · · ·	, -, -, -,

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY9,805,6509,594,297

As of September 30, 2015, total assets increased by Euro 211.4 million to Euro 9,805.7 million, compared to Euro 9,594.3 million as of December 31, 2014.

In the first nine months of 2015, non-current assets increased by Euro 211.4 million, mainly due to an increase in intangible assets (including goodwill) of Euro 164.2 million, an increase in property, plant and

Table of Contents

equipment of Euro 54.5 million and an increase in deferred tax assets of Euro 7.7 million and it is partially offset by the decrease in other assets of Euro (16.2) million.

The increase in intangible assets was due to the positive effects of foreign currency fluctuations of Euro 210.1 million and to the additions in the period of Euro 107.3 million which were partially offset by amortization in the period of Euro 151.0 million.

The increase in property, plant and equipment was due to the positive currency fluctuation effects of Euro 46.3 million as of September 30, 2015 compared to December 31, 2014, to the additions in the period of Euro 225.4 million and partially offset by depreciation in the period of Euro 201.4 million.

As of September 30, 2015 as compared to December 31, 2014:

Accounts receivable increased by Euro 83.3 million, primarily due to (i) the increase in net sales during the first nine months of 2015 and (ii) the seasonality of the Group's business which is generally characterized by higher sales in the first part of the year and collection of the related receivables in the second part of the year;

Inventories increased by Euro 94.4 million which is aimed at improving the quality of the customer experience by having at any time inventory levels in line with customer demand;

Accounts payable increased by Euro 40.4 million, primarily due to the increase in volumes in the first nine months of 2015 and to the strengthening of certain currencies in which the Group operates;

Current taxes payable increased by Euro 132.1 million due to the timing of tax payments made by the Group in various jurisdictions; and

Employee benefits increased by Euro 7.4 million which was primarily due to the streightening of the US Dollar compared to the Euro during the first nine months of 2015.

Our net financial position as of September 30, 2015 and December 31, 2014 was as follows:

(Amounts in thousands of Euro)	September 30, 2015	December 31, 2014
Cash and cash equivalents	1,314,432	1,453,587
Bank overdrafts	(110,663)	(151,303)
Current portion of long-term debt	(554,557)	(626,788)
Long-term debt	(1,699,265)	(1,688,415)
Total net financial position	(1,050,054)	(1,012,918)

Bank overdrafts consist of the utilized portion of short-term uncommitted revolving credit lines borrowed by various subsidiaries of the Group. The interest rate applied to these credit lines depends on the currency and is usually floating.

As of September 30, 2015, Luxottica together with our wholly-owned Italian subsidiaries had credit lines aggregating Euro 246.3 million. The interest rate is a floating rate of EURIBOR plus a margin on average of approximately 137 basis points. At September 30, 2015, Euro 0.6 million was utilized under these credit lines.

As of September 30, 2015, our wholly-owned subsidiary Luxottica U.S. Holdings Corp. maintained unsecured lines of credit with an aggregate maximum availability of Euro 116.0 million (USD 130.0 million converted at the applicable exchange rate for the period ended September 30, 2015). The interest is at a floating rate of approximately LIBOR plus 50 basis points. At September 30, 2015, these credit lines

were not utilized but Euro 43.8 million in aggregate face amount of standby letters of credit were outstanding as of period end.

Table of Contents

4. RELATED PARTY TRANSACTIONS

Our related party transactions are neither atypical nor unusual and occur in the ordinary course of our business. Management believes that these transactions are fair to the Company. These transactions are managed as arms-length market transactions. For further details regarding related party transactions, please refer to Note 29 of the Notes to the Consolidated Financial Statements as of September 30, 2015.

On January 29, 2013 the Company elected to avail itself of the options provided by Article 70, Section 8, and Article 71, Section 1- bis, of CONSOB Issuers' Regulations and, consequently, will no longer comply with the obligation to make available to the public an information memorandum in connection with transactions involving significant mergers, spin-offs, increases in capital through contributions in kind, acquisitions and disposals.

5. SUBSEQUENT EVENTS

For further details regarding any subsequent events, please refer to Note 35 to the Condensed Consolidated Financial Statements as of September 30, 2015.

6. 2015 OUTLOOK

The financial results reported for the first nine months of 2015 lead management to an optimistic outlook for the full fiscal year primarily driven by the strong performance of the Group's brand portfolio.

NON-IFRS MEASURES

Adjusted measures

In this Management Report we refer to certain performance measures that are not in accordance with IFRS. Such non-IFRS measures are not meant to be considered in isolation or as a substitute for items appearing on our financial statements prepared in accordance with IFRS. Rather, these non-IFRS measures should be used as a supplement to IFRS results to assist the reader in better understanding our operational performance.

Such measures are not defined terms under IFRS and their definitions should be carefully reviewed and understood by investors. Such non-IFRS measures are explained in detail and reconciled to their most comparable IFRS measures below.

In order to provide a supplemental comparison of current period results of operations to prior periods, we have adjusted for certain non-recurring transactions or events.

In the first nine months of 2015, we made adjustments to the following measures: net sales, cost of sales, selling expenses, general and administrative expenses, EBITDA, operating income, net income, income taxes and earnings per share. We adjusted the above items for the modification of the EyeMed reinsurance agreement referenced above (the "EyeMed Adjustment") with an impact for the nine-month period ended September 30, 2015 equal to Euro 130.0 million and for Oakley integration costs and other minor project costs of Euro 34.1 million (Euro 28.9 million net of tax).

In the first nine months of 2014, we made adjustments to the following measures: net sales, cost of sales, general and administrative expenses, EBITDA, operating income, net income, income taxes and earnings per share. We adjusted the above items for the EyeMed Adjustment for the nine-month period ended September 30, 2014 equal to Euro 22.7 million and for non-recurring expenses related to the termination of the former Group CEO for Euro 15.0 million (Euro 10.9 million net of taxes).

The adjusted measures referenced above are not measures of performance in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board and endorsed by the European Union. The Group believes that these adjusted measures are useful

13

Table of Contents

to both management and investors in evaluating the Group's operating performance compared with that of other companies in its industry in order to provide a supplemental view of operations that exclude items that are unusual, infrequent or unrelated to our ongoing operations.

Non IFRS measures such as EBITDA, EBITDA margin, free cash flow and the ratio of net debt to EBITDA are included in this Management Report in order to:

improve transparency for investors;

assist investors in their assessment of the Group's operating performance and its ability to refinance its debt as it matures and incur additional indebtedness to invest in new business opportunities;

assist investors in their assessment of the Group's cost of debt;

ensure that these measures are fully understood in light of how the Group evaluates its operating results and leverage;

properly define the metrics used and confirm their calculation; and

share these measures with all investors at the same time.

See the tables below for a reconciliation of the adjusted measures discussed above to their most directly comparable IFRS financial measures. For a reconciliation of EBITDA to its most directly comparable IFRS measure, see the pages following the tables below (Amounts in millions of Euro):

Luxottica Group	9M 2015					
	Net	Cost of		Operating	Net	Base
	sales	Sales	EBITDA	Income	Income	EPS
Reported	6,821.7	(2,165.2)	1,548.5	1,196.2	704.8	1.47
> EyeMed Adjustment	130.0	(130.0)				
> Oakley's integration and other minor project						
costs			34.1	34.1	28.9	0.06
Adjusted	6,951.7	(2,295.3)	1,582.6	1,230.3	733.7	1.53

Luxottica Group	9M 2014					
	Net	Cost of		Operating	Net	Base
	sales	Sales	EBITDA	Income	Income	EPS
Reported	5,785.3	(1,955.4)	1,227.6	947.5	555.0	1.17
> EyeMed Adjustment	22.7	(22.7)				
> Termination of the former Group						
CEO			15.0	15.0	10.9	0.02
Adjusted	5,808.0	(1,978.0)	1,242.6	962.5	565.9	1.19

EBITDA and EBITDA margin

EBITDA represents net income attributable to Luxottica Group stockholders, before non-controlling interests, provision for income taxes, other income/expense, depreciation and amortization. EBITDA margin means EBITDA divided by net sales. We believe that EBITDA is useful to both management and investors in evaluating our operating performance compared to that of other companies in our industry. Our calculation of EBITDA allows us to compare our operating results with those of other companies without giving effect to financing, income taxes and the accounting effects of capital spending, which items may vary for different companies for reasons unrelated to the overall operating performance of a company's business.

Table of Contents

EBITDA and EBITDA margin are not meant to be considered in isolation or as a substitute for items appearing in our financial statements prepared in accordance with IFRS. Rather, these non-IFRS measures should be used as a supplement to IFRS results to assist the reader in better understanding the operational performance of the Group. For additional information on the Group's non-IFRS measures used in this report, see "NON-IFRS MEASURES *Adjusted Measures*" set forth above.

Investors should be aware that our method of calculating EBITDA may differ from methods used by other companies. We recognize that the usefulness of EBITDA has certain limitations, including:

EBITDA does not include interest expense. Because we have borrowed money in order to finance our operations, interest expense is a necessary element of our costs and ability to generate profits and cash flows. Therefore, any measure that excludes interest expense may have material limitations;

EBITDA does not include depreciation and amortization expense. Because we use capital assets, depreciation and amortization expense is a necessary element of our costs and ability to generate profits. Therefore, any measure that excludes depreciation and amortization expense may have material limitations;

EBITDA does not include provision for income taxes. Because the payment of income taxes is a necessary element of our costs, any measure that excludes tax expense may have material limitations;

EBITDA does not reflect cash expenditures or future requirements for capital expenditures or contractual commitments;

EBITDA does not reflect changes in, or cash requirements for, working capital needs;

EBITDA does not allow us to analyze the effect of certain recurring and non-recurring items that materially affect our net income or loss.

We compensate for the foregoing limitations by using EBITDA as a comparative tool, together with IFRS measurements, to assist in the evaluation of our operating performance and leverage. The following

Table of Contents

table provides a reconciliation of EBITDA to net income, which is the most directly comparable IFRS financial measure, as well as the calculation of EBITDA margin on net sales:

Non-IFRS Measure: EBITDA and EBITDA margin

Millions of Euro	9M 2014	9M 2015	FY 2014	LTM September 30, 2015
Net income/(loss) (+)	555.0	704.8	642.6	792.4
Net income attributable to non-controlling interest (+)	4.0	2.1	3.4	1.5
Provision for income taxes (+)	316.4	413.4	414.1	511.1
Other (income)/expense (+)	72.1	75.8	97.5	101.2
Depreciation and amortization (+)	280.0	352.4	384.0	456.3
EBITDA (=)	1,227.6	1,548.5	1,541.6	1,862.6
Net sales (/)	5,785.3	6,821.7	7,652.3	8,688.7
EBITDA margin (=)	21.2%	22.7%	20.1%	21.4%

Non-IFRS Measure: Adjusted EBITDA and Adjusted EBITDA margin

Millions of Euro	9M 2014 ^(1,3)	9M 2015 ^(1,4)	FY 2014 ^(1,2,3)	LTM September 30, 2015 ^(1,2,3,4)
Adjusted net income/(loss) (+)	565.9	733.7	687.4	855.2
Net income attributable to non-controlling interest (+)	4.0	2.1	3.4	1.5
Adjusted provision for income taxes (+)	320.5	418.6	389.2	487.3
Other (income)/expense (+)	72.1	75.8	97.5	101.2
Depreciation and amortization (+)	280.0	352.4	384.0	456.3
Adjusted EBITDA (=)	1,242.6	1,582.6	1,561.6	1,901.7
Net sales	5,808.0	6,951.7	7,698.9	8,842.7

(/)							
Adjuste (=)	d EBITDA margin	21.4%	22.8%	20.3%	21.5%		
The adju	sted figures:						
(1) Include the EyeMed Adjustment. Starting from July 1, 2014 following the modification of an EyeMed reinsurance agreement with an existing underwriter, the Group assumes less reinsurance revenues and less claims expense. The impact of the contract for the twelve-month period ended December 31, 2014 was Euro 46.6 million, for the nine month-period ended September 30, 2014 was Euro 22.7 million, for the nine-month period ended September 30, 2015 was Euro 130.0 million and in the fourth quarter of 2014 was Euro 23.9 million.							
(2)	Exclude the accrual for the tax audit relating to Luxottica	S.r.l. (fiscal ye	ears from 2008	to 2011) of appr	oximately Euro 30.0 million.		
16							

Table of Contents

(3)

Exclude non-recurring costs of approximately Euro 20.0 million (Euro 14.5 million net of tax) related to the departure of two former Group CEOs in 2014. For the nine month-period ended September 30, 2014 the impact was Euro 15.0 million (Euro 10.9 million net of tax).

(4)

Exclude approximately Euro 34.1 million (Euro 28.9 million net of tax) related to the integration of Oakley and other minor project costs.

Free Cash Flow

Free cash flow represents EBITDA, as defined above, plus or minus the decrease/(increase) in working capital over the period, less capital expenditures, plus or minus interest income/(expense) and extraordinary items, minus taxes paid. Our calculation of free cash flow provides a clearer picture of our ability to generate net cash from operations, which is used for mandatory debt service requirements, to fund discretionary investments, pay dividends or pursue other strategic opportunities. For additional information on Group's non-IFRS measures used in this report, see "NON-IFRS MEASURES *Adjusted Measures*" set forth above.

Free cash flow is not meant to be considered in isolation or as a substitute for items appearing on our financial statements prepared in accordance with IFRS. Rather, this non-IFRS measure should be used as a supplement to IFRS results to assist the reader in better understanding the operational performance of the Group.

The Group cautions that this measure is not a defined term under IFRS and its definition should be carefully reviewed and understood by investors.

Investors should be aware that our method of calculation of free cash flow may differ from methods used by other companies. We recognize that the usefulness of free cash flow as an evaluative tool may have certain limitations, including:

The manner in which we calculate free cash flow may differ from that of other companies, which limits its usefulness as a comparative measure;

Free cash flow does not represent the total increase or decrease in the net debt balance for the period since it excludes, among other things, cash used for funding discretionary investments and to pursue strategic opportunities during the period and any impact of the exchange rate changes; and

Free cash flow can be subject to adjustment at our discretion if we take steps or adopt policies that increase or diminish our current liabilities and/or changes to working capital.

We compensate for the foregoing limitations by using free cash flow as one of several comparative tools, together with IFRS measurements, to assist in the evaluation of our operating performance.

Table of Contents

The following table provides a reconciliation of free cash flow to EBITDA and the table above provides a reconciliation of EBITDA to net income, which is the most directly comparable IFRS financial measure:

Non-IFRS Measure: Free cash flow

(Amounts in millions of Euro)	9M 2015
Adjusted EBITDA ⁽¹⁾	1,583
Δ working capital	(128)
Capex	(333)
Operating cash flow	1,121
Financial charges ⁽²⁾	(75)
Taxes	(350)
Other net	(2)
Free cash flow	695

(1)

Adjusted EBITDA is not an IFRS measure; please see table above for a reconciliation of EBITDA to net income.

(2)

Equals interest income minus interest expenses.

(3)

Equals extraordinary income minus extraordinary expenses.

Net debt to EBITDA ratio

Net debt represents the sum of bank overdrafts, the current portion of long-term debt and long-term debt, less cash. The ratio of net debt to EBITDA is a measure used by management to assess the Group's level of leverage, which affects our ability to refinance our debt as it matures and incur additional indebtedness to invest in new business opportunities. The ratio also allows management to assess the cost of existing debt since it affects the interest rates charged by the Company's lenders.

EBITDA and the ratio of net debt to EBITDA are not meant to be considered in isolation or as a substitute for items appearing on our financial statements prepared in accordance with IFRS. Rather, these non-IFRS measures should be used as a supplement to IFRS results to assist the reader in better understanding the operational performance of the Group. For additional information on Group's non-IFRS measures used in this report, see "NON-IFRS MEASURES *Adjusted Measures*" set forth above.

The Group cautions that these measures are not defined terms under IFRS and their definitions should be carefully reviewed and understood by investors.

Investors should be aware that Luxottica Group's method of calculating EBITDA and the ratio of net debt to EBITDA may differ from methods used by other companies.

The Group recognizes that the usefulness of EBITDA and the ratio of net debt to EBITDA as evaluative tools may have certain limitations. The ratio of net debt to EBITDA is net of cash and cash equivalents, restricted cash and short-term investments, thereby reducing our debt position.

Because we may not be able to use our cash to reduce our debt on a dollar-for-dollar basis, this measure may have material limitations. We compensate for the foregoing limitations by using EBITDA and the ratio of net debt to EBITDA as two of several comparative tools, together with IFRS measurements, to assist in the evaluation of our operating performance and leverage.

See the table below for a reconciliation of net debt to long-term debt, which is the most directly comparable IFRS financial measure, as well as the calculation of the ratio of net debt to EBITDA. For a reconciliation of EBITDA to its most directly comparable IFRS measure, see the table on the earlier page.

Non-IFRS Measure: Net debt and Net debt/EBITDA

(Amounts in millions of Euro)	September 30, 2015	December 31, 2014
Long-term debt (+)	1,699.3	1,688.4
Current portion of long-term debt (+)	554.6	626.8
Bank overdrafts (+)	110.7	151.3
Cash ()	(1,314.4)	(1,453.6)
Net debt (=)	1,050.1	1,012.9
LTM EBITDA	1,862.6	1,541.6
Net debt/EBITDA	0.6x	0.7x
Net debt @ avg. exchange rates ⁽¹⁾	1,046.7	984.3
Net debt @ avg. exchange rates ⁽¹⁾ /EBITDA	0.6x	0.6x

(1)

Net debt figures are calculated using the average exchange rates used to calculate the EBITDA figures.

Non-IFRS Measure: Net debt and Net debt/Adjusted EBITDA

(Amounts in millions of Euro)	September 30, 2015 ^{(2(b))}	December 31, 2014 ^{(2(a))}
Long-term debt (+)	1,699.3	1,688.4
Current portion of long-term debt (+)	554.6	626.8
Bank overdrafts (+)	110.7	151.3
Cash ()	(1,314.4)	(1,453.6)
Net debt (=)	1,050.1	1,012.9
LTM Adjusted EBITDA	1,901.7	1,561.6
Net debt/LTM Adjusted EBITDA Net debt @ avg. exchange rates ⁽¹⁾	0.6x	0.6x

			1,046.7	984.3
Net debt	@ avg. 6	exchange rates ⁽¹⁾ /LTM EBITDA	0.6x	0.6x
(1)	Net debt	figures are calculated using the average exchange	rates used to calculate the E	BITDA figu
(2)	Adjusted	l figures exclude:		
	(a)			
		The non-recurring expenses related to the depart income and Euro 14.5 million impact on net inco	1	EOs with an a
	(b)	Costs related to the integration of Oakley and otl	her minor projects with an i	mpact of Eur
		Euro 28.9 million impact on net income.		

Table of Contents

FORWARD-LOOKING INFORMATION

Throughout this report, management has made certain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 which are considered prospective. These statements are made based on management's current expectations and beliefs and are identified by the use of forward-looking words and phrases such as "plans," "estimates," "believes" or "belief," "expects" or other similar words or phrases.

Such statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those which are anticipated. Such risks and uncertainties include, but are not limited to, our ability to manage the effect of the uncertain current global economic conditions on our business, our ability to successfully acquire new businesses and integrate their operations, our ability to predict future economic conditions and changes in consumer preferences, our ability to successfully introduce and market new products, our ability to maintain an efficient distribution network, our ability to achieve and manage growth, our ability to negotiate and maintain favorable license arrangements, the availability of correction alternatives to prescription eyeglasses, fluctuations in exchange rates, changes in local conditions, our ability to protect our proprietary rights, our ability to maintain our relationships with host stores, any failure of our information technology, inventory and other asset risk, credit risk on our accounts, insurance risks, changes in tax laws, as well as other political, economic, legal and technological factors and other risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date hereof, and we do not assume any obligation to update them.

ITEM 2. FINANCIAL STATEMENTS

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(Amounts in thousands of Euro)	Note reference	September 30, 2015 ^(*)	December 31, 2014
ASSETS			
CURRENT ASSETS:			
Cash and cash equivalents	6	1,314,432	1,453,587
Accounts receivable	7	837,618	754,306
Inventories	8	822,849	728,404
Other assets	9	192,714	231,397
Total current assets		3,167,614	3,167,695
NON-CURRENT ASSETS:			
Property, plant and equipment	10	1,372,162	1,317,617
Goodwill	11	3,489,986	3,351,263
Intangible assets	11	1,410,001	1,384,501
Investments	12	62,269	61,176
Other assets	13	107,670	123,848
Deferred tax assets	14	195,949	188,199
Total non-current assets		6,638,037	6,426,603
TOTAL ASSETS		9,805,650	9,594,297
LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES:			
Short-term borrowings	15	110,663	151,303
Current portion of long-term debt	16	554,557	626,788
Accounts payable	10	784,671	744,272
Income taxes payable	18	174,685	42,603
Short term provisions for risks and other charges	19	127,318	187,719
Other liabilities	20	616,057	636,055
Total current liabilities		2,367,951	2,388,740
NON-CURRENT LIABILITIES:			
Long-term debt	21	1,699,265	1,688,415
Employee benefits	22	145,923	138,475
Deferred tax liabilities	14	254,175	266,896
Long term provisions for risks and other charges	23	91,240	99,223
Other liabilities	24	89,578	83,770
Total non-current liabilities		2,280,182	2,276,778
STOCKHOLDERS' EQUITY:			
Capital stock	25	29,007	28,900
Legal reserve	25	5,785	5,736

Reserves	25	4,484,852	4,318,124
Treasury shares	25	(71,239)	(73,875)
Net income	25	704,768	642,596
Luxottica Group stockholders' equity	25	5,153,171	4,921,479
Non-controlling interests	26	4,347	7,300
Total stockholders' equity		5,157,519	4,928,779
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		9,805,650	9,594,297

(*)

Unaudited

CONSOLIDATED STATEMENT OF INCOME

		Three Months ended		Nine Months ended		
	Note	Septemb 2015 ^(*)	er 30 2014 ^(*)	Septemb 2015 ^(*)	er 30 2014 ^(*)	
(Amounts in thousands of Euro) ⁽¹⁾	reference	2015	2014	2015	2014	
Net sales	27	2,154,976	1,882,969	6,821,688	5,785,282	
Cost of sales	27	689,125	605,552	2,165,220	1,955,366	
Gross profit		1,465,851	1,277,417	4,656,468	3,829,916	
Selling	27	691,083	590,457	2,088,281	1,710,560	
Royalties	27	41,079	36,722	130,644	112,352	
Advertising	27	135,319	132,408	441,294	381,202	
General and administrative	27	260,749	236,633	800,099	678,260	
Total operating expenses		1,128,230	996,221	3,460,318	2,882,375	
Income from operations		337,621	281,196	1,196,150	947,541	
Other income/(expense)			i i i i i i i i i i i i i i i i i i i		, i i i i i i i i i i i i i i i i i i i	
Interest income	27	2,583	3,154	7,967	8,994	
Interest expense	27	(25,651)	(27,445)	(84,347)	(80,764)	
Other net	27	(179)	(14)	531	(367)	
Income before provision for income						
taxes		314,374	256,891	1,120,301	875,405	
Provision for income taxes	27	(114,254)	(93,706)	(413,411)	(316,373)	
Net income	21	200,120	163,185	706,891	559,031	
Net income		200,120	105,105	700,091	559,051	
Of which attributable to:		100 (55				
Luxottica Group stockholders		199,655	162,442	704,768	554,982	
Non-controlling interests		465	743	2,123	4,049	
NET INCOME		200,120	163,185	706,891	559,031	
Weighted average number of shares						
outstanding:						
Basic	30	480,078,163	477,019,093	479,259,114	475,325,386	
Diluted	30	481,390,247	479,202,804	481,003,224	478,351,143	
EPS:						
Basic	30	0.42	0.34	1.47	1.17	
Diluted	30	0.41	0.34	1.47	1.16	

Except per share data

(*) Unaudited

22

⁽¹⁾

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

		Three Months ended September 30		Nine Months ended September 30	
(Amounts in thousands of Euro)	2015 ^(*)	2014 ^(*)	2015 ^(*)	2014 ^(*)	
Net income	200,120	163,185	706,891	559,031	
Other comprehensive income:					
Items that may be reclassified subsequently to profit or loss:					
Currency translation differences	(128,968)	239,560	137,961	311,373	
Total items that may be reclassified subsequently to profit or loss:	(128,968)	239,560	137,961	311,373	
Items that will not be reclassified to profit or loss:					
Actuarial gain on defined benefit plans	(54,896)	(10,953)	(7,761)	(45,502)	
Related tax effect	23,230	5,448	8,861	19,840	